Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.12 (-1.12%) Market Cap: 616.66 Mil Enterprise Value: -40.99 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at RBC Capital Markets Healthcare Conference Transcript

May 21, 2019 / 07:35PM GMT
Release Date Price: €145.1 (-2.68%)
Brian Corey Abrahams
RBC Capital Markets, LLC, Research Division - Senior Analyst

Everyone, I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next presenting company is Sage Therapeutics, represented by their CFO, Kimi Iguchi; and their Chief Research Officer, Jim Doherty. Thanks guys for joining us.

Jim Doherty
Sage Therapeutics, Inc. - Chief Research Officer

Thanks for having us.

Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer

Thank you.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, LLC, Research Division - Senior Analyst

So maybe we should start on the commercial front, and the brexanolone or ZULRESSO upcoming launch. Drug was just approved a couple of months ago so congratulations on your first drug approval. Where do you guys stand with respect to launch preparations and timelines there?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot